Efficacy [qlco]    
Safety [hcpp]    
therapy [ftcn]    
Diabetes [dsyn]    
Complicated [ftcn]    
Chronic Liver Disease [dsyn]    
HEPATITIS C VIRUS [virs]    
Diabetes [dsyn]    
Present [qnco]    
Patients [podg]    
Chronic Liver Disease [dsyn]    
HEPATITIS C VIRUS [virs]    
Case-Control Study [resa]    
Efficacy [qlco]    
Safety [hcpp]    
Dipeptidyl peptidase IV inhibitor [phsu]    
DIABETES MELLITUS, TYPE II [dsyn]    
Chronic Liver Disease [dsyn]    
HEPATITIS C VIRUS [virs]    
Methods [inpr]    
Sixteen [qnco]    
Hepatitis C virus positive [lbtr]    
Patients [podg]    
DIABETES MELLITUS, TYPE II [dsyn]    
Treated [ftcn]    
Patients [podg]    
GIVEN [cnce]    
December [qlco]    
January [qlco]    
HEPATITIS C VIRUS [virs]    
Patients [podg]    
DIABETES MELLITUS, TYPE II [dsyn]    
Treated [ftcn]    
Diet [food]    
WEEKS [tmco]    
Selected [acty]    
Control Group [grup]    
SERUM [bdsu]    
Levels [qlco]    
FASTING [fndg]    
Plasma glucose [lbpr]    
AST [tmco]    
ALT [neop]    
Measured [qlco]    
WEEKS [tmco]    
Initiation [menp]    
treatment [ftcn]    
Group [idcn]    
Average [qnco]    
Decreased [qnco]    
Approximately [qlco]    
WEEKS [tmco]    
Initiation [menp]    
Average [qnco]    
fasting plasma glucose level [lbpr]    
Decreased [qnco]    
Approximately [qlco]    
mg dl [qnco]    
Initiation [menp]    
Patients [podg]    
Able [orga]    
Take [hlca]    
mg day [qnco]    
Reduction [npop]    
Related [qlco]    
side effects [ftcn]    
HAND [bpoc]    
Control Group [grup]    
Average [qnco]    
fasting plasma glucose level [lbpr]    
Statistical Significance [qnco]    
WEEKS [tmco]    
Average [qnco]    
AST [tmco]    
ALT [neop]    
WEEKS [tmco]    
Group [idcn]    
Control Group [grup]    
effective [qlco]    
treatment [ftcn]    
DIABETES MELLITUS, TYPE II [dsyn]    
Complicated [ftcn]    
Hepatitis C virus positive [lbtr]    
Chronic Liver Disease [dsyn]    
